Human IL-4 Protein, His Tag (MALS verified)
分子別名(Synonym)
IL-4,BCGF1,BSF1
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-4, His Tag (IL4-H52H9) is expressed from human 293 cells (HEK293). It contains AA His 25 - Ser 153 (Accession # P05112-1).
Predicted N-terminus: His 25
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.9 kDa. The protein migrates as 22-24 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素4是一種誘導(dǎo)幼稚輔助T細(xì)胞(Th0細(xì)胞向Th2細(xì)胞)分化的細(xì)胞因子。在IL-4和IL-13的存在下,Th1型反應(yīng)中產(chǎn)生的細(xì)胞因子,特別是在過(guò)敏和寄生蟲(chóng)感染期間,巨噬細(xì)胞會(huì)被不同程度地激活,這種細(xì)胞因子是白細(xì)胞介素4受體的配體。白細(xì)胞介素4受體也與IL13結(jié)合,這可能導(dǎo)致該細(xì)胞因子和IL13的許多重疊功能。STAT6是一種信號(hào)轉(zhuǎn)導(dǎo)子和轉(zhuǎn)錄激活子,已被證明在介導(dǎo)這種細(xì)胞因子的免疫調(diào)節(jié)信號(hào)中起著核心作用。最近,研究人員發(fā)現(xiàn),細(xì)胞因子IL-4在幾種基因缺陷小鼠品系(包括Itk、KLF2、CBP和Id3)胸腺中先天CD8+T細(xì)胞的發(fā)育中起著關(guān)鍵作用,這些小鼠品系以前沒(méi)有接觸過(guò)抗原。
關(guān)鍵字: IL-4;IL-4蛋白;IL-4重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。